<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Retrovirology</journal-id><journal-title>Retrovirology</journal-title><issn pub-type="epub">1742-4690</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1742-4690-1-45</article-id><article-id pub-id-type="pmid">15613239</article-id><article-id pub-id-type="doi">10.1186/1742-4690-1-45</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Inhibition of HIV-1 replication in primary human monocytes by the I&#x003ba;B-&#x003b1;S32/36A repressor of NF-&#x003ba;B</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Palmieri</surname><given-names>Camillo</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>cpalmieri@unicz.it</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Trimboli</surname><given-names>Francesca</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>trimboli@unicz.it</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Puca</surname><given-names>Antimina</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>puca@dbbm.unina.it</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Fiume</surname><given-names>Giuseppe</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>fiume@dbbm.unina.it</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Scala</surname><given-names>Giuseppe</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>scala@unicz.it</email></contrib><contrib id="A6" corresp="yes" contrib-type="author"><name><surname>Quinto</surname><given-names>Ileana</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>quinto@unicz.it</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Clinical and Experimental Medicine, University of Catanzaro "Magna Graecia", Via T. Campanella 115, 88100 Catanzaro, Italy</aff><aff id="I2"><label>2</label>Department of Biochemistry and Medical Biotechnology, University of Naples "Federico II", Via S. Pansini 5, 80131 Naples, Italy</aff><pub-date pub-type="collection"><year>2004</year></pub-date><pub-date pub-type="epub"><day>21</day><month>12</month><year>2004</year></pub-date><volume>1</volume><fpage>45</fpage><lpage>45</lpage><ext-link ext-link-type="uri" xlink:href="http://www.retrovirology.com/content/1/1/45"/><history><date date-type="received"><day>13</day><month>12</month><year>2004</year></date><date date-type="accepted"><day>21</day><month>12</month><year>2004</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2004 Palmieri et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2004</copyright-year><copyright-holder>Palmieri et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Palmieri Camillo cpalmieri@unicz.it </dc:author><dc:title> Inhibition of HIV-1 replication in primary human monocytes by the I&#x003ba;B-&#x003b1;S32/36A repressor of NF-&#x003ba;B </dc:title><dc:date>2004</dc:date><dcterms:bibliographicCitation>Retrovirology 1(1): 45-. (2004)</dcterms:bibliographicCitation><dc:identifier type="sici">1742-4690(2004)1:1&#x0003c;45&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1742-4690</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>The identification of the molecular mechanisms of human immunodeficiency virus type 1, HIV-1, transcriptional regulation is required to develop novel inhibitors of viral replication. NF-&#x003ba;B transacting factors strongly enhance the HIV/SIV expression in both epithelial and lymphoid cells. Controversial results have been reported on the requirement of NF-&#x003ba;B factors in distinct cell reservoirs, such as CD4-positive T lymphocytes and monocytes. We have previously shown that I&#x003ba;B-&#x003b1;S32/36A, a proteolysis-resistant inhibitor of NF-&#x003ba;B, potently inhibits the growth of HIV-1 and SIVmac239 in cell cultures and in the SIV macaque model of AIDS. To further extend these observations, we have generated NL(AD8)I&#x003ba;B-&#x003b1;S32/36A, a macrophage-tropic HIV-1 recombinant strain endowed to express I&#x003ba;B-&#x003b1;S32/36A.</p></sec><sec><title>Results</title><p>In this work, we show that infection with NL(AD8)I&#x003ba;B-&#x003b1;S32/36A down-regulated the NF-&#x003ba;B DNA binding activity in cells. NL(AD8)I&#x003ba;B-&#x003b1;S32/36A was also highly attenuated for replication in cultures of human primary monocytes.</p></sec><sec><title>Conclusions</title><p>These results point to a major requirement of NF-&#x003ba;B activation for the optimal replication of HIV-1 in monocytes and suggest that agents which interfere with NF-&#x003ba;B activity could counteract HIV-1 infection of monocytes-macrophages <italic>in vivo</italic>.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>HIV-1 infection is characterized by a long period of clinical latency followed by the development of acquired immunodeficiency syndrome, AIDS. During latency and when viral replication is being controlled in patients treated with antiretroviral therapy, HIV-1 is present in cellular reservoirs and continues to replicate, with each ensuing round of replication giving rise to escape mutants, which further replenish viral reservoirs [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. This grim picture calls for novel targeted therapies for eradicating virus-infected cells and for preventing new infections.</p><p>Initial infection <italic>in vivo </italic>by HIV-1 is thought to occur in CD4-positive, CCR5-positive lymphocytes and monocytes. Accordingly, when HIV-1 envelope protein in its oligomerized g160 form contacts the cell surface receptor a signalling cascade is triggered that results in transcriptional activation of specific gene arrays, such as the inflammatory cytokines IL-1 &#x003b2;, IL-6, IL-8, TNF-&#x003b1;, TGF-&#x003b2;; these cytokines, in turn, function to enhance the transcriptional activity of the proviral long terminal repeat (LTR) promoter [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. This cytokine-driven inflammatory-like setting is mediated molecularly by the NF-&#x003ba;B family of transcription factors [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>]; thus, it serves to reason that preventing NF-&#x003ba;B activation would attenuate HIV-1 replication. Indeed, the LTR of HIV-1 does contain two tandem NF-&#x003ba;B sites [<xref ref-type="bibr" rid="B7">7</xref>] and three repeated Sp1 sites [<xref ref-type="bibr" rid="B8">8</xref>] upstream of the TATAA box with an additional NF-&#x003ba;B site located in the 5' untranslated region of viral genome [<xref ref-type="bibr" rid="B9">9</xref>]. Both sets of NF-&#x003ba;B sequences enhance HIV-1 transcription in response to various signals [<xref ref-type="bibr" rid="B9">9</xref>]. However, the Sp1 sites and TATAA box can redundantly sustain the Tat-mediated transactivation of the HIV-1 LTR in the absence of NF-&#x003ba;B sites [<xref ref-type="bibr" rid="B10">10</xref>]. It is controversial whether NF-&#x003ba;B cellular factors are required for the HIV-1 replication. Mutant HIV-1 carrying deletions or base-pair substitutions in the NF-&#x003ba;B enhancer in the LTR have been shown to be either competent or incompetent for replication [<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B13">13</xref>]. These divergent observations are likely explained by differing cellular contexts, such as primary cells versus immortalized cell lines, and varying levels of cellular activation.</p><p>I&#x003ba;B inhibitors regulate NF-&#x003ba;B activity [<xref ref-type="bibr" rid="B14">14</xref>]. In response to activating stimuli, I&#x003ba;B proteins become phosphorylated, ubiquinated and degraded by proteasomes. This releases cytoplasmic-sequestered NF-&#x003ba;B to enter the nucleus to activate the transcription of responsive genes [<xref ref-type="bibr" rid="B14">14</xref>]. The mutant I&#x003ba;B-&#x003b1;S32/36A is defective for serine 32- and serine 36-phosphorylation and is resistant to proteolysis. I&#x003ba;B-&#x003b1;S32/36A acts as a potent inhibitor of the NF-&#x003ba;B-dependent gene transcription, including those from the HIV-1 genome [<xref ref-type="bibr" rid="B15">15</xref>]. To verify the requirement of NF-&#x003ba;B in the replication of HIV-1 in primary cells, we previously designed HIV-1 and SIV molecular clones containing the I&#x003ba;B-&#x003b1;S32/36A cDNA positioned into the <italic>nef </italic>region of the respective viral genome [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>]. We found that these recombinant viruses were highly attenuated for replication in T cell lines as well as in human and simian PHA-activated peripheral blood mononuclear cells, PBMCs [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>]. These findings supported an interpretation that in these cellular contexts NF-&#x003ba;B is required for efficient viral replication. We also showed that a recombinant SIV which expressed I&#x003ba;B-&#x003b1;S32/36A inhibitor was also highly replication attenuated <italic>in vivo </italic>in rhesus macaque [<xref ref-type="bibr" rid="B17">17</xref>]. Here, we have extended our analysis of I&#x003ba;B-&#x003b1;S32/36A function in HIV-1 replication to primary monocytes. We report that a macrophage-tropic derivative of NL4-3 strain that expresses the proteolysis-resistant I&#x003ba;B-&#x003b1;S32/36A inhibitor of NF-&#x003ba;B replicated poorly in cultured primary human monocytes.</p></sec><sec><title>Results</title><sec><title>Construction of pNL(AD8)I&#x003ba;B-&#x003b1;S32/36A</title><p>To generate a macrophage-tropic HIV-1 expressing the I&#x003ba;B-&#x003b1;S32/36A cDNA fused to the FLAG epitope, the CXCR4-tropic envelope of pNLI&#x003ba;B-&#x003b1;S32/36A [<xref ref-type="bibr" rid="B16">16</xref>] was replaced with the CCR5-tropic envelope from pNL(AD8) [<xref ref-type="bibr" rid="B18">18</xref>]. Briefly, the 2.7 Kb EcoR1-BamH1 fragment of pNL(AD8) was religated to the 13.1 Kb EcoR1-BamH1 fragment of pNLI&#x003ba;B-&#x003b1;S32/36A or pNLI&#x003ba;B-antisense, thus generating pNL(AD8)I&#x003ba;B-&#x003b1;S32/36A and pNL(AD8)I&#x003ba;B-antisense, respectively (Fig. <xref ref-type="fig" rid="F1">1A</xref>). Both molecular clones are Nef-minus because our cloning strategy deleted the first 39 amino acids from the N terminus of Nef and engineered a translational frameshift into the remaining Nef-encoding codons [<xref ref-type="bibr" rid="B16">16</xref>]. The respective molecular clones were transfected into 293T cells to analyse for the expression of HIV-1 proteins and I&#x003ba;B-&#x003b1;S32/36A polypeptide by immunoblotting (Fig. <xref ref-type="fig" rid="F1">1 B, C</xref>). As expected the I&#x003ba;B-&#x003b1;S32/36A-FLAG protein was expressed by pNL(AD8)I&#x003ba;B-&#x003b1;S32/36A (Fig. <xref ref-type="fig" rid="F1">1C</xref>, lane 4).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Genome structure and expression of recombinant pNL(AD8)I&#x003ba;B-&#x003b1;S32/36A and pNL(AD8)I&#x003ba;B-antisense molecular genomes. </bold>Panel A shows the structure of pNL(AD8) derivatives that carry the I&#x003ba;B-&#x003b1;S32/36A-FLAG insert into the <italic>nef </italic>region in sense (pNL(AD8)I&#x003ba;B-&#x003b1;S32/36A) or antisense (pNL(AD8)I&#x003ba;B-antisense) orientations. Panel B shows the immunoblot analysis using hyperimmune AIDS patient serum of total extracts (10 &#x003bc;g) from 293T cells 24 hours after transfection with the indicated viral plasmids (10 &#x003bc;g). Panel C shows the immunoblot analysis using an anti-FLAG monoclonal antibody of total extracts (10 &#x003bc;g) from 293T cells 24 h after transfection with the indicated viral plasmids (10 &#x003bc;g).</p></caption><graphic xlink:href="1742-4690-1-45-1"/></fig></sec><sec><title>Inhibition of NF-&#x003ba;B activity by pNL(AD8)I&#x003ba;B-&#x003b1;S32/36A</title><p>To assess the functional impact of I&#x003ba;B-&#x003b1;S32/36A expressed from the recombinant NL(AD8) genome, 293T cells were transfected individually with pNL(AD8), pNL(AD8)I&#x003ba;B-&#x003b1;S32/36A or pNL(AD8)I&#x003ba;B-antisense, and the respective nuclear extracts were evaluated for NF-&#x003ba;B (Fig. <xref ref-type="fig" rid="F2">2A</xref>) and Sp1 DNA binding activity (Fig. <xref ref-type="fig" rid="F2">2B</xref>). A significant reduction in NF-&#x003ba;B DNA binding activity was observed upon transfection of pNL(AD8)I&#x003ba;B-&#x003b1;S32/36A (Fig. <xref ref-type="fig" rid="F2">2A</xref>, lane 5) as compared to the other viral transfections (Fig. <xref ref-type="fig" rid="F2">2A</xref>, lanes 3,4). The specificity of the I&#x003ba;B&#x003b1;S32/36A-mediated inhibition of NF-&#x003ba;B was verified by the demonstration that Sp1 binding to DNA was unaffected (Fig. <xref ref-type="fig" rid="F2">2B</xref>). These results support the interpretation that I&#x003ba;B&#x003b1;S32/36A expressed from the recombinant viral genome functionally inhibited NF-&#x003ba;B activity.</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Reduced NF-&#x003ba;B DNA binding activity in cells transfected with pNL(AD8)I&#x003ba;B-&#x003b1;S32/36A. </bold>Panel A shows the NF-&#x003ba;B binding activity of nuclear extracts (5 &#x003bc;g) from 293 T cells transfected with the indicated viral plasmids (10 &#x003bc;g) or were mock-transfected. Panel C shows the Sp1 binding activity of the same nuclear extracts as in panel A. Binding competitions were performed with 100-fold molar excess of the respective unlabelled oligonucleotide.</p></caption><graphic xlink:href="1742-4690-1-45-2"/></fig></sec><sec><title>Attenuation of pNL(AD8)I&#x003ba;B-&#x003b1;S32/36A in primary monocytes</title><p>We next analyzed the replication properties of the recombinant HIV-1 genomes in cultured human monocytes from different individuals. Based on normalized amounts of input virus, we found that NL(AD8)I&#x003ba;B-&#x003b1;S32/36A was highly attenuated for replication when compared to NL(AD8) and NL(AD8)I&#x003ba;B-antisense (Fig. <xref ref-type="fig" rid="F3">3 A-B</xref>). Accordingly, virus-induced syncitium formation was also strongly inhibited in monocytes infected with NL(AD8)I&#x003ba;B-aS32/36A (Fig. <xref ref-type="fig" rid="F4">4 A, B</xref>). Taken together, our results underscore a critical contribution of NF-&#x003ba;B to HIV-1 growth in monocytes.</p><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>Attenuated replication of NL(AD8)I&#x003ba;B-&#x003b1;S32/36A in primary human monocytes. </bold>Panels A and B show the growth NL(AD8), NL(AD8)I&#x003ba;B-antisense and NL(AD8)I&#x003ba;B-&#x003b1;S32/36A in cultures of primary human monocytes. Cells (10<sup>5</sup>) were infected with equal amounts of viruses normalized based on RT counts of 10<sup>6 </sup>cpm (A) or 10<sup>5 </sup>cpm (B). A representative experiment of three independent infections of monocytes from different individuals is shown.</p></caption><graphic xlink:href="1742-4690-1-45-3"/></fig><fig position="float" id="F4"><label>Figure 4</label><caption><p><bold>Reduced syncitia formation by NL(AD8)I&#x003ba;B-&#x003b1;S32/36A in infection of primary human monocytes. </bold>Panel A shows the kinetics of syncitia generation upon infection of primary human monocytes with 10<sup>5 </sup>cpm RT activity of the indicated viral stocks. The average of syncitia observed per optical field is reported. Panel B shows the picture of primary human monocytes at 14 days post-infection with 10<sup>5 </sup>cpm RT activity of the indicated viral stocks (original magnification &#x000d7; 430).</p></caption><graphic xlink:href="1742-4690-1-45-4"/></fig></sec></sec><sec><title>Discussion</title><p>Substantial numbers of monocytes are preserved in infected individuals even at later clinical stages of AIDS, when T cell numbers are dramatically reduced. Consistently, in animal models of HIV-1 infection, monocytes are the major reservoir after acute depletion of CD4-positive T cells [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref>]. This indicates that these cells are long lasting infected moieties that shuttle from mucosal sites to lymph nodes and could function as a major HIV-1 reservoir <italic>in vivo</italic>. In addition, monocytes are programmed to produce a large amount of inflammatory cytokine, including IL1-&#x003b2;, IL-6, TNF-&#x003b1;, which are strong inducers of HIV-1 replication [<xref ref-type="bibr" rid="B5">5</xref>]. Indeed, HIV-1 envelope binding to CCR5 receptor activates an intracellular signalling cascade that promotes high levels of transcription factors, including NF-&#x003ba;B, which sustain the initial rounds of viral replication and induce the production of inflammatory cytokines which activate surrounding cells to become more susceptible to virus infection [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>].</p><p>Based on the published literature, the role of NF-&#x003ba;B in HIV-1 replication has been controversial [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B21">21</xref>]. For instance, the deletion of NF-&#x003ba;B binding sites from HIV-1 and SIV LTRs [<xref ref-type="bibr" rid="B22">22</xref>] has suggested that NF-&#x003ba;B activity may not be required for HIV-1 LTR-directed transcription. Moreover, deletion of NF-&#x003ba;B sequences in the LTR has also been reported not to affect HIV-1 replication in defined cellular settings [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>]. These latter studies relied on short-term infections of immortalized cells that may not express a physiologic concentration of transcription factors. To address this issue, we have developed a novel HIV-1 strain, NL(AD8)I&#x003ba;B-&#x003b1;S32/36A, which was engineered to express a proteolysis-resistant I&#x003ba;B&#x003b1;S32/36A, and is a strong inhibitor of NF-&#x003ba;B activity. This recombinant virus expresses the envelope of the AD8 strain, a macrophage-tropic virus. Our findings show that NL(AD8)I&#x003ba;B-&#x003b1;S32/36A replication profile is different from that of the NL(AD8)I&#x003ba;B-antisense control. NL(AD8)I&#x003ba;B-&#x003b1;S32/36A failed to produce a productive infection in primary monocytic cells over a thirty-days acute infection (Fig. <xref ref-type="fig" rid="F3">3</xref>). These results were correlated with a strong inhibition NF-&#x003ba;B activity in NL(AD8)I&#x003ba;B-&#x003b1;S32/36A-infected cells (Fig. <xref ref-type="fig" rid="F2">2</xref>), indicating that in the setting of HIV infection of primary monocytes NF-&#x003ba;B plays a non-redundant role. These results are in agreement with the evidence that I&#x003ba;B-&#x003b1;S32/36A negatively affected the replication of HIV and SIV in PBMC cultures and in monkeys [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>].</p><p>Because I&#x003ba;B-&#x003b1;S32/36A constitutively inhibits NF-&#x003ba;B [<xref ref-type="bibr" rid="B15">15</xref>], the potent inhibition of HIV/SIV replication could be due to repression of the NF-&#x003ba;B-dependent activation of HIV/SIV transcription. However, additional mechanisms might explain the potent inhibition of HIV/SIV replication by I&#x003ba;B-&#x003b1;S32/36A. In this regard, I&#x003ba;B-&#x003b1; regulates the transcriptional activity of NF-&#x003ba;B-independent genes by interacting with nuclear co-repressors, histone acetyltransferases and deacetylases [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref>]. Further studies are required to clarify novel activities of I&#x003ba;B-&#x003b1; in the modulation of the transcriptional machinery. Our results underscore a central role for I&#x003ba;B-&#x003b1; as a potent inhibitor of the replication of HIV-1 in both T cells [<xref ref-type="bibr" rid="B16">16</xref>] and monocytes (this study), and point to the NF-&#x003ba;B/I&#x003ba;B network as a suitable target for therapeutic intervention of AIDS.</p></sec><sec><title>Conclusions</title><p>In this study we have addressed the role of NF-&#x003ba;B/I&#x003ba;B proteins in the replication of HIV-1 in primary human monocytes. We show a strong attenuation in the replication of a macrophage-tropic HIV-1 strain expressing the I&#x003ba;B-&#x003b1;S32/36A repressor of NF-&#x003ba;B in primary cultures of human monocytes. These results are consistent with previous evidence of HIV/SIV inhibition by I&#x003ba;B-&#x003b1;S32/36A in PBMCs and in macaques [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>]. In addition, these findings further support a role of NF-&#x003ba;B inhibitors in blocking HIV-1 replication and suggest novel strategies for the development of anti-viral therapy that targets NF-&#x003ba;B factors.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Transfections and Viral stocks</title><p>293T cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% v/v heat-inactivated fetal bovine serum and 3 mM glutamine. Viral stocks were produced by transfecting 293T cells (10<sup>6</sup>) with viral plasmids (10 &#x003bc;g) using calcium phosphate. Forty hours later, the cell culture supernatant was passed through a 0.45-&#x003bc;m filter and measured for RT activity as previously described [<xref ref-type="bibr" rid="B16">16</xref>].</p></sec><sec><title>Immunoblotting analysis</title><p>293T cells were transfected with viral plasmids (10 &#x003bc;g) and lysed in RIPA buffer (150 mM NaCl, 1 % Nonidet P-40, 0.5 % sodium deoxycholate, 0.1% sodium dodecyl sulfate, 50 mM Tris-HCl pH 8.0) 24 hours later. Proteins (10&#x003bc;g) were separated by electrophoresis in 10% SDS-polyacrylamide gel and transferred to Immobilon-P (Millipore). Filters were blotted with an AIDS patient serum or with anti-FLAG monoclonal antibody by using Western-Light Chemiluminescent Detection System (Tropix, Bedford, MA).</p></sec><sec><title>Electrophoretic Mobility Shift Assays</title><p>Nuclear extracts and gel retardation assays were performed as described previously [<xref ref-type="bibr" rid="B9">9</xref>]. Briefly, cells were harvested, washed twice in cold phosphate-buffered saline, and resuspended in lysing buffer (10 mM Hepes, pH 7.9, 1 mM EDTA, 60 mM KCl, 1 mM DTT, 1 mM phenylmethylsulfonyl fluoride, 0.2% v/v Nonidet P-40) for 5 min. Nuclei were collected by centrifugation (500 &#x000d7; <italic>g</italic>, 5 min), rinsed with Nonidet P-40-free lysing buffer, and resuspended in 150 &#x003bc;l of buffer containing 250 mM Tris-HCl, pH 7.8, 20% glycerol, 60 mM KCl, 1 mM DTT, 1 mM phenylmethylsulfonyl fluoride. Nuclei were then subjected to three cycles of freezing and thawing. The suspension was cleared by centrifugation (7000 &#x000d7; <italic>g</italic>, 15 min), and aliquots were immediately tested in gel retardation assay or stored in liquid phase N2 until use. The HIV-1 NF-&#x003ba;B oligonucleotide probe was 5'-CAAGGGACTTTCCGCTGGGGACTTTCCAG-3'; the Sp1 oligonucleotide probe was 5'-GGGAGGTGTGGCCTGGGCGGGACTGGGGAGTGGCG-3'. The probes were end-labelled with [&#x003b3;-<sup>32</sup>P]ATP (Amersham Int., Buckinghamshire, UK) using polynucleotide kinase (New England Biolabs, Beverly, MA). Equal amounts (5 &#x003bc;g) of cell extracts were incubated in a 20 &#x003bc;l reaction mixture containing 10% glycerol, 60 mM KCl, 1 mM EDTA, 1 mM DTT, and 2 &#x003bc;g of poly [d(G-C)] (Boehringer Mannheim, Germany) for 5 min on ice. One &#x003bc;l of [&#x003b3;<sup>32</sup>P]-labelled double-stranded probe (0.2 ng, 5 &#x000d7; 10<sup>4 </sup>cpm) was then added with or without a 100-fold molar excess of competitor oligonucleotide. The reactions were incubated at room temperature for 15 min and run on a 6% acrylamide:bisacrylamide (30:1) gel in 22.5 mM Tris borate, 0.5 mM EDTA. Gels were dried and autoradiographed.</p></sec><sec><title>Monocytes cultures and infections</title><p>Human monocytes were isolated from PBMC by elutriation, cultured in RPMI, 10% FCS and GMCSF (20 ng/ml) for 48 hours. Infections were performed with viral stocks measured by reverse-transcriptase (RT) activity [<xref ref-type="bibr" rid="B16">16</xref>]. Usually, cell cultures (10<sup>5 </sup>cells) were infected with 10<sup>5 </sup>- 10<sup>6 </sup>cpm of RT activity. The cell culture supernatants were collected every two days and replaced with fresh medium. The viral production was measured as RT activity in the culture supernatants as previously described [<xref ref-type="bibr" rid="B16">16</xref>]. The syncitia formation in cell cultures was evaluated by calculating the average number of syncitia in at least six optical fields.</p></sec></sec><sec><title>List of abbreviations used</title><p>NF-&#x003ba;B, nuclear factor kappa B</p><p>I&#x003ba;B, inhibitor of nuclear factor kappa B</p><p>IL-1, interleukin-1</p><p>IL-6, interleukin-6</p><p>IL-8, interleukin-8</p><p>TNF-&#x003b1;, tumor necrosis factor alpha</p><p>TGF-&#x003b2;, transforming growth factor-beta</p><p>cpm, counts per minute</p><p>FCS, fetal calf serum</p><p>GMCSF, granulocyte-macrophage colony-stimulating factor</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>CP carried out the analysis of viral growth and DNA band-shift assays. FT was responsible for cell cultures. AP performed the immunoblotting analysis. GF produced the viral plasmids and viral stocks, and performed the artwork of the paper. GS participated in the design of the study and discussion of results. IQ designed this study and edited the manuscript.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>We thank K. T. Jeang for helpful discussions, and E. Freed for providing pNL(AD8). This work was supported by Ministero della Sanit&#x000e0;-Istituto Superiore della Sanit&#x000e0;-Programma Nazionale di Ricerca sull'AIDS, and Ministero dell'Istruzione, dell'Universit&#x000e0; e della Ricerca. C.P and A.P were recipients of FIRC fellowships.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chun</surname><given-names>TW</given-names></name><name><surname>Davey</surname><given-names>RT</given-names></name><name><surname>Ostrowski</surname><given-names>M</given-names></name><name><surname>Justemente</surname><given-names>JS</given-names></name><name><surname>Engel</surname><given-names>D</given-names></name><name><surname>Mullins</surname><given-names>JI</given-names></name><name><surname>Fauci</surname><given-names>AS</given-names></name></person-group><article-title>Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy</article-title><source>Nat Med</source><year>2000</year><volume>6</volume><fpage>757</fpage><lpage>761</lpage><pub-id pub-id-type="pmid">10888923</pub-id><pub-id pub-id-type="doi">10.1038/77481</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chun</surname><given-names>TW</given-names></name><name><surname>Stuyver</surname><given-names>L</given-names></name><name><surname>Mizel</surname><given-names>SB</given-names></name><name><surname>Ehler</surname><given-names>LA</given-names></name><name><surname>Mican</surname><given-names>JA</given-names></name><name><surname>Baseler</surname><given-names>M</given-names></name><name><surname>Lloyd</surname><given-names>AL</given-names></name><name><surname>Novak</surname><given-names>M</given-names></name><name><surname>Fauci</surname><given-names>AS</given-names></name></person-group><article-title>Presence of an inducibile HIV-1 latent reservoir during highly active antiretroviral therapy</article-title><source>Proc Natl Acad Sci USA</source><year>1997</year><volume>94</volume><fpage>13193</fpage><lpage>13197</lpage><pub-id pub-id-type="pmid">9371822</pub-id><pub-id pub-id-type="doi">10.1073/pnas.94.24.13193</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Devadas</surname><given-names>K</given-names></name><name><surname>Hardegen</surname><given-names>NJ</given-names></name><name><surname>Whal</surname><given-names>LM</given-names></name><name><surname>Hewlett</surname><given-names>IK</given-names></name><name><surname>Clouse</surname><given-names>KA</given-names></name><name><surname>Yamada</surname><given-names>KM</given-names></name><name><surname>Dhawan</surname><given-names>S</given-names></name></person-group><article-title>Mechanism for macrophage-mediated HIV-1 induction</article-title><source>J Immunol</source><year>2004</year><volume>173</volume><fpage>6735</fpage><lpage>6744</lpage><pub-id pub-id-type="pmid">15557166</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rieckmann</surname><given-names>P</given-names></name><name><surname>Poli</surname><given-names>G</given-names></name><name><surname>Kehrl</surname><given-names>JH</given-names></name><name><surname>Fauci</surname><given-names>AS</given-names></name></person-group><article-title>Activated B lymphocytes from human immunodeficiency virus-infected individuals induce virus expression in infected T cells and a promonocytic cel line U1</article-title><source>J Exp Med</source><year>1991</year><volume>173</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">1985116</pub-id><pub-id pub-id-type="doi">10.1084/jem.173.1.1</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hiscott</surname><given-names>J</given-names></name><name><surname>Kwon</surname><given-names>H</given-names></name><name><surname>G&#x000e9;nin</surname><given-names>P</given-names></name></person-group><article-title>Hostile takeovers: viral appropriation of the NF-&#x003ba;B pathway</article-title><source>J Clin Invest</source><year>2001</year><volume>107</volume><fpage>143</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">11160127</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Faure</surname><given-names>E</given-names></name><name><surname>Lecine</surname><given-names>P</given-names></name><name><surname>Lipcey</surname><given-names>C</given-names></name><name><surname>Champino</surname><given-names>S</given-names></name><name><surname>Imbert</surname><given-names>J</given-names></name></person-group><article-title>Cell-to-cell contact activate the long terminal repeat of human immunodeficiency virus 1 through its NF-&#x003ba;B motif</article-title><source>Eur J Biochem</source><year>1997</year><volume>244</volume><fpage>568</fpage><lpage>574</lpage><pub-id pub-id-type="pmid">9119025</pub-id><pub-id pub-id-type="doi">10.1111/j.1432-1033.1997.00568.x</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nabel</surname><given-names>G</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name></person-group><article-title>An inducibile transcription factor activates expression of human immunodeficiency virus in T cells</article-title><source>Nature</source><year>1987</year><volume>326</volume><fpage>711</fpage><lpage>713</lpage><pub-id pub-id-type="pmid">3031512</pub-id><pub-id pub-id-type="doi">10.1038/326711a0</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>KA</given-names></name><name><surname>Kadonaga</surname><given-names>JT</given-names></name><name><surname>Luciw</surname><given-names>PA</given-names></name><name><surname>Tijan</surname><given-names>R</given-names></name></person-group><article-title>Activation of AIDS retrovirus promoter by the cellular transcription factor, Sp1</article-title><source>Science</source><year>1986</year><volume>232</volume><fpage>755</fpage><lpage>759</lpage><pub-id pub-id-type="pmid">3008338</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mallardo</surname><given-names>M</given-names></name><name><surname>Dragonetti</surname><given-names>E</given-names></name><name><surname>Baldassarre</surname><given-names>F</given-names></name><name><surname>Ambrosino</surname><given-names>C</given-names></name><name><surname>Scala</surname><given-names>G</given-names></name><name><surname>Quinto</surname><given-names>I</given-names></name></person-group><article-title>An NF-&#x003ba;B sites in the 5'-untraslated leader region of the human immunodeficiency virus type 1 enhances the viral exression in response to NF-&#x003ba;B-activating stimuli</article-title><source>J Biol Chem</source><year>1996</year><volume>271</volume><fpage>20820</fpage><lpage>20827</lpage><pub-id pub-id-type="pmid">8702837</pub-id><pub-id pub-id-type="doi">10.1074/jbc.271.34.20820</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berkhout</surname><given-names>B</given-names></name><name><surname>Jeang</surname><given-names>KT</given-names></name></person-group><article-title>Functional roles for the TATA promoter and enhancers in basal and Tat-induced expression of the human immunodeficiency virus type 1 long terminal repeat</article-title><source>J Virol</source><year>1992</year><volume>66</volume><fpage>139</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">1727476</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leonard</surname><given-names>J</given-names></name><name><surname>Parrot</surname><given-names>C</given-names></name><name><surname>Buckler-White</surname><given-names>J</given-names></name><name><surname>Turner</surname><given-names>W</given-names></name><name><surname>Ross</surname><given-names>EK</given-names></name><name><surname>Martin</surname><given-names>MA</given-names></name><name><surname>Rabson</surname><given-names>AB</given-names></name></person-group><article-title>The NF-&#x003ba;B binding sites in the human immunodeficiency virus type 1 long terminal repeat are not required for virus infectivity</article-title><source>J Virol</source><year>1989</year><volume>63</volume><fpage>4919</fpage><lpage>4924</lpage><pub-id pub-id-type="pmid">2795721</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>EK</given-names></name><name><surname>Buckler-White</surname><given-names>AJ</given-names></name><name><surname>Rabson</surname><given-names>AB</given-names></name><name><surname>Englund</surname><given-names>G</given-names></name><name><surname>Marin</surname><given-names>MA</given-names></name></person-group><article-title>Contribution of NF-&#x003ba;B and Sp1 binding motifs to the replicative capacity of human immunodeficiency virus type 1: distinct patterns of viral growth are determined by T-cell types</article-title><source>J Virol</source><year>1991</year><volume>65</volume><fpage>4350</fpage><lpage>4358</lpage><pub-id pub-id-type="pmid">2072454</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alcami</surname><given-names>J</given-names></name><name><surname>Lain de Lera</surname><given-names>T</given-names></name><name><surname>Folgueira</surname><given-names>L</given-names></name><name><surname>Pedraza</surname><given-names>MA</given-names></name><name><surname>Jacque</surname><given-names>JM</given-names></name><name><surname>Bachelerie</surname><given-names>F</given-names></name><name><surname>Noriega</surname><given-names>AR</given-names></name><name><surname>Hay</surname><given-names>RT</given-names></name><name><surname>Harrich</surname><given-names>D</given-names></name><name><surname>Gaynor</surname><given-names>RB</given-names></name></person-group><article-title>Absolute dependence on kappa B responsive elements for initiation and Tat-mediated amplification of HIV-1 transcription in blood CD4 T lymphocytes</article-title><source>EMBO J</source><year>1995</year><volume>14</volume><fpage>1552</fpage><lpage>1560</lpage><pub-id pub-id-type="pmid">7729429</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>LF</given-names></name><name><surname>Greene</surname><given-names>WC</given-names></name></person-group><article-title>Shaping the nuclear action of NF-kappaB</article-title><source>Nat Rev Mol Cell Biol</source><year>2004</year><volume>5</volume><fpage>392</fpage><lpage>401</lpage><pub-id pub-id-type="pmid">15122352</pub-id><pub-id pub-id-type="doi">10.1038/nrm1368</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>K</given-names></name><name><surname>Gerstberger</surname><given-names>S</given-names></name><name><surname>Carlson</surname><given-names>L</given-names></name><name><surname>Franzoso</surname><given-names>G</given-names></name><name><surname>Siebenlist</surname><given-names>U</given-names></name></person-group><article-title>Control of I&#x003ba;B-&#x003b1; proteolysis by site-specific, signal-induced phosphorylation</article-title><source>Science</source><year>1995</year><volume>267</volume><fpage>1485</fpage><lpage>1488</lpage><pub-id pub-id-type="pmid">7878466</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Quinto</surname><given-names>I</given-names></name><name><surname>Mallardo</surname><given-names>M</given-names></name><name><surname>Baldassarre</surname><given-names>F</given-names></name><name><surname>Scala</surname><given-names>G</given-names></name><name><surname>Englund</surname><given-names>G</given-names></name><name><surname>Jeang</surname><given-names>KT</given-names></name></person-group><article-title>Potent and stable attenuation of Live-HIV-1 by gain of a proteolysis-resistant inhibitor of NF-&#x003ba;B (I&#x003ba;B-&#x003b1;S32/36A) and the implications for vaccine development</article-title><source>J Biol Chem</source><year>1999</year><volume>274</volume><fpage>17567</fpage><lpage>17572</lpage><pub-id pub-id-type="pmid">10364191</pub-id><pub-id pub-id-type="doi">10.1074/jbc.274.25.17567</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Quinto</surname><given-names>I</given-names></name><name><surname>Puca</surname><given-names>A</given-names></name><name><surname>Greenhouse</surname><given-names>J</given-names></name><name><surname>Silvera</surname><given-names>P</given-names></name><name><surname>Yalley-Ognuro</surname><given-names>J</given-names></name><name><surname>Lewis</surname><given-names>MG</given-names></name><name><surname>Palmieri</surname><given-names>C</given-names></name><name><surname>Trimboli</surname><given-names>F</given-names></name><name><surname>Byrum</surname><given-names>R</given-names></name><name><surname>Adelsberger</surname><given-names>J</given-names></name><name><surname>Venzon</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Scala</surname><given-names>G</given-names></name></person-group><article-title>High attenuation and immunogenicity of a simiam immunodeficiency virus expressing a proteolysis-resistant inhibitor of NF-&#x003ba;B</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>1720</fpage><lpage>1728</lpage><pub-id pub-id-type="pmid">14593121</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M309375200</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Freed</surname><given-names>EO</given-names></name><name><surname>Englund</surname><given-names>G</given-names></name><name><surname>Martin</surname><given-names>MA</given-names></name></person-group><article-title>Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection</article-title><source>J Virol</source><year>1995</year><volume>69</volume><fpage>3949</fpage><lpage>3954</lpage><pub-id pub-id-type="pmid">7745752</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Orenstein</surname><given-names>JM</given-names></name><name><surname>Fox</surname><given-names>C</given-names></name><name><surname>Wahl</surname><given-names>SM</given-names></name></person-group><article-title>Macrophages as a source of HIV during opportunistic infections</article-title><source>Science</source><year>1997</year><volume>276</volume><fpage>1857</fpage><lpage>1861</lpage><pub-id pub-id-type="pmid">9188531</pub-id><pub-id pub-id-type="doi">10.1126/science.276.5320.1857</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Igarashi</surname><given-names>T</given-names></name><name><surname>Imamichi</surname><given-names>H</given-names></name><name><surname>Brown</surname><given-names>CR</given-names></name><name><surname>Hirsch</surname><given-names>VM</given-names></name><name><surname>Martin</surname><given-names>MA</given-names></name></person-group><article-title>The emergence and characterization of macrophage-tropic SIV/HIV chimeric viruses (SHIVs) present in CD4+ T cell-depleted rhesus monkeys</article-title><source>J Leukoc Biol</source><year>2003</year><volume>74</volume><fpage>772</fpage><lpage>780</lpage><pub-id pub-id-type="pmid">14595005</pub-id><pub-id pub-id-type="doi">10.1189/jlb.0503196</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>H</given-names></name><name><surname>Pelletier</surname><given-names>N</given-names></name><name><surname>DeLuca</surname><given-names>C</given-names></name><name><surname>Genin</surname><given-names>P</given-names></name><name><surname>Cisternas</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>R</given-names></name><name><surname>Wainberg</surname><given-names>MA</given-names></name><name><surname>Hiscott</surname><given-names>J</given-names></name></person-group><article-title>Inducible expression of IkappaBalpha repressor mutants interferes with NF-kappaB activity and HIV-1 replication in Jurkat T cells</article-title><source>J Biol Chem</source><year>1998</year><volume>273</volume><fpage>7431</fpage><lpage>7440</lpage><pub-id pub-id-type="pmid">9516441</pub-id><pub-id pub-id-type="doi">10.1074/jbc.273.13.7431</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yedavalli</surname><given-names>VS</given-names></name><name><surname>Benkirane</surname><given-names>M</given-names></name><name><surname>Jeang</surname><given-names>KT</given-names></name></person-group><article-title>Tat and trans-activation-responsive (TAR) RNA-independent induction of HIV-1 long terminal repeat by human and murine cyclin T1 requires Sp1</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>6404</fpage><lpage>6410</lpage><pub-id pub-id-type="pmid">12458222</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M209162200</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Viatour</surname><given-names>P</given-names></name><name><surname>Legrand-Poels</surname><given-names>S</given-names></name><name><surname>van Lint</surname><given-names>C</given-names></name><name><surname>Warnier</surname><given-names>M</given-names></name><name><surname>Merville</surname><given-names>MP</given-names></name><name><surname>Gielen</surname><given-names>J</given-names></name><name><surname>Piette</surname><given-names>J</given-names></name><name><surname>Bours</surname><given-names>V</given-names></name><name><surname>Chariot</surname><given-names>A</given-names></name></person-group><article-title>Cytoplasmic IkappaBalpha increases NF-kappaB-independent transcription through binding to histone deacetylase (HDAC) 1 and HDAC3</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>46541</fpage><lpage>46548</lpage><pub-id pub-id-type="pmid">12972430</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M306381200</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aguilera</surname><given-names>C</given-names></name><name><surname>Hoya-Arias</surname><given-names>R</given-names></name><name><surname>Haegeman</surname><given-names>G</given-names></name><name><surname>Espinosa</surname><given-names>L</given-names></name><name><surname>Bigas</surname><given-names>A</given-names></name></person-group><article-title>Recruitment of IkappaBalpha to the hes1 promoter is associated with transcriptional repression</article-title><source>Proc Natl Acad Sci U S A</source><year>2004</year><volume>101</volume><fpage>16537</fpage><lpage>16542</lpage><pub-id pub-id-type="pmid">15536134</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0404429101</pub-id></citation></ref></ref-list></back></article> 